Tom 15, Nr 4 (2018)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2018-12-13
Pobierz cytowanie

Sulodeksyd w opinii lekarzy praktyków — głosy farmakologa klinicznego, kardiologa, hematologa, chirurga naczyniowego, internisty i ortopedy

Filip M. Szymański, Krystyna Zawilska, Zbigniew Krasiński, Paweł Łęgosz, Paweł Małdyk, Katarzyna Życińska, Krzysztof J. Filipiak
Choroby Serca i Naczyń 2018;15(4):211-225.
Tom 15, Nr 4 (2018)
Zalecenia i stanowiska
Opublikowany online: 2018-12-13

Streszczenie

Brak

Streszczenie

Brak
Pobierz cytowanie
Informacje o artykule
Tytuł

Sulodeksyd w opinii lekarzy praktyków — głosy farmakologa klinicznego, kardiologa, hematologa, chirurga naczyniowego, internisty i ortopedy

Czasopismo

Choroby Serca i Naczyń

Numer

Tom 15, Nr 4 (2018)

Typ artykułu

Wytyczne / stanowisko ekspertów

Strony

211-225

Data publikacji on-line

2018-12-13

Rekord bibliograficzny

Choroby Serca i Naczyń 2018;15(4):211-225.

Autorzy

Filip M. Szymański
Krystyna Zawilska
Zbigniew Krasiński
Paweł Łęgosz
Paweł Małdyk
Katarzyna Życińska
Krzysztof J. Filipiak

Referencje (82)
  1. Harenberg J, Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998; 18(1): 1–20.
  2. Hoppensteadt DA, Fareed J, Hoppensteadt DA, et al. Pharmacological profile of sulodexide. Int Angiol. 2014; 33: 229.
  3. Fiore G, Baraldi A, Gambarotta GC, et al. Inhibition of plasminoagen activator (PAI-1) by sulodexide in post-thrombophlebotic patients. J Drug Invest. 1992; 3: 173–178.
  4. Coccheri S, Coccheri S. Biological and clinical effects of sulodexide in arterial disorders and diseases. Intern Angiol. 2014; 33(3): 263–274.
  5. Tomaniak M, Gąsecka A, Filipiak KJ, et al. Cell-derived microvesicles in cardiovascular diseases and antiplatelet therapy monitoring - A lesson for future trials? Current evidence, recent progresses and perspectives of clinical application. Int J Cardiol. 2017; 226: 93–102.
  6. Ceriello A, Quatraro A, Ettorre M, et al. Glucosaminoglycans administration decreases fibrinogen in plasma levels in diabetic patients. Diabetes Nutr Metab. 1993; 6(4): 203–206.
  7. Castelluccio A, Bologna E, Castelluccio A, et al. Effect of sulodexide on blood viscosity in patients with peripheral vascular disease. Curr Med Res Opin. 1991; 12(5): 325–331.
  8. Kim SB, Kim SuH, Lee MS, et al. Effects of sulodexide on hemostatic factors, lipid profile, and inflammation in chronic peritoneal dialysis patients. Perit Dial Int. 2007; 27(4): 456–460.
  9. Tiozzo R, Cingi MR, Pietrangelo A, et al. Effect of heparin-like compounds on the in vitro proliferation and protein synthesis of various cell types. Arzneimittel-Forschung. 1989; 39(1): 15–20.
  10. Połubińska A, Staniszewski R, Baum E, et al. Sulodexide modifies intravascular homeostasis what affects function of the endothelium. Adv Med Sci. 2013; 58(2): 304–310.
  11. van Haare J, Kooi ME, van Teeffelen JW, et al. Metformin and sulodexide restore cardiac microvascular perfusion capacity in diet-induced obese rats. Cardiovasc Diabetol. 2017; 16(1): 47.
  12. Sosińska P, Baum E, Maćkowiak B, et al. Sulodexide reduces the proinflammatory effect of serum from patients with peripheral artery disease in human arterial endothelial cells. Cell Physiol Biochem. 2016; 40(5): 1005–1012.
  13. Sumińska-Jasińska K, Połubińska A, Ciszewicz M, et al. Sulodexide reduces senescence-related changes in human endothelial cells. Med Sci Monit. 2011; 17(4): CR222–CR226.
  14. Mannello F, Raffetto JD, et al. Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research. Am J Transl Res. 2011; 3(2): 149–158.
  15. Mattana P, Mannello F, Ferrari P, et al. Vascular pathologies and inflammation: the anti-inflammatory properties of sulodexide. J Vasc Endovasc Surg. 2012; 19(2 (Suppl 3)): 1–7.
  16. Mannello F, Medda V, Ligi D, et al. Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases. Curr Vasc Pharmacol. 2013; 11(3): 354–365.
  17. Urbanek T, Zbigniew K, Begier-Krasińska B, et al. Sulodexide suppresses inflammation in patients with chronic venous insufficiency. Int Angiol. 2015; 34(6): 589–596.
  18. Borawski J, Dubowski M, Pawlak K, et al. Effect of sulodexide on plasma transforming growth factor-beta1 in healthy volunteers. Clin Appl Thromb Hemost. 2010; 16(1): 60–65.
  19. Bręborowicz A. Sulodeksyd — mieszanina glikozaminoglikanów o protekcyjnym działaniu w stosunku do komórek śródbłonka naczyniowego. Acta Angiol. 2014; 3: 112–118.
  20. Coccheri S, Mannello F, et al. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2013; 8: 49–65.
  21. Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010; 53(12): 2646–2655.
  22. Masola V, Onisto M, Zaza G, et al. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med. 2012; 10: 213.
  23. Zhao Q, Yin J, Lu Z, et al. Sulodexide Protects Contrast-Induced Nephropathy in Sprague-Dawley Rats. Cell Physiol Biochem. 2016; 40(3–4): 621–632.
  24. Li R, Xing J, Mu X, et al. Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review. Drug Des Devel Ther. 2015; 9: 6275–6283.
  25. Linkins LA, Choi PT, Douketis JD, et al. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003; 139(11): 893–900.
  26. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007; 120(8): 700–705.
  27. Agnelli G, Büller HR, Cohen A, et al. AMPLIFY-EXT Investigators, AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368(8): 699–708.
  28. Schulman S, Kearon C, Kakkar AK, et al. RE-MEDY Trial Investigators, RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013; 368(8): 709–718.
  29. Bauersachs R, Berkowitz SD, Brenner B, et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26): 2499–2510.
  30. Andreozzi GM, Bignamini AA, Davì G, et al. SURVET Study Investigators, SURVET Study Investigators. Sulodexide for the prevention of recurrent venous thromboembolism: the sulodexide in secondary prevention of recurrent deep vein thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial. Circulation. 2015; 132(20): 1891–1897.
  31. Adiguzel C, Iqbal O, Hoppensteadt D, et al. Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide. Clin Appl Thromb Hemost. 2009; 15(5): 501–511.
  32. Mast AE. Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein. Arterioscler Thromb Vasc Biol. 2016; 36(1): 9–14.
  33. Camire RM, Camire RM. Rethinking events in the haemostatic process: role of factor V and TFPI. Haemophilia. 2016; 22: 3–8.
  34. Andreozzi GM. Editorial: sulodexide, an old drug with recent renewed interest. Curr Vasc Pharmacol. 2013; 11(3): 352–353.
  35. Borawski J, Naumnik B, Dubowski M, et al. Full-length TFPI release by heparinoid sulodexide. Clin Appl Thromb Hemost. 2010; 16(4): 485–487.
  36. Borawski J, Dubowski M, Rydzewska-Rosolowska A, et al. Intravenous and oral sulodexide versus coagulation activation markers in humans. Clin Appl Thromb Hemost. 2009; 15(5): 596–598.
  37. Fareed J. Personal communication. Wydawnictwo? Miejsce wydania. ; 2016.
  38. Mannarino E, Pasqualini L, Ciuffetti G, et al. Effect of oral administration of sulodexide on fibrinolysis and plasma viscosity: a pilot study. Drug Investigation. 2012; 4(4): 346–350.
  39. Fiore G, Baraldi A, Gambarotta GC, et al. Inhibition of plasminogen activator (PAI-1) by sulodexide in post-thrombophlebotic patients. J Drug Dev. 1991; 3: 173–178.
  40. Mauro M, Ferraro G, Palmieri GC, et al. Profibrinolytic and antithrombotic effects of sulodexide oral administration: a double-blind, cross-over, placebo-controlled study. Curr Ther Res. 1992; 51: 342–350.
  41. Urbanek T, Krasinski Z, Sumińska-Jasińska K, et al. Sulodexide reduces the inflammatory reaction and senescence of endothelial cells in conditions involving chronic venous disease. Int Angiol. 2016; 35(2): 140–147.
  42. Corsi C, Bocci L, Cipriani C, et al. The effectiveness of glycosaminoglycans in peripheral vascular disease therapy: a clinical and experimental trial. J Int Med Res. 1985; 13(1): 40–47.
  43. Crepaldi G, Fellin R, Calabrò A, et al. Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use. Atherosclerosis. 1990; 81(3): 233–243.
  44. Coccheri S, Scondotto G, Agnelli G, et al. Arterial Arm of the Suavis (Sulodexide Arterial Venous Italian Study) group. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J. 2002; 23(13): 1057–1065.
  45. Gaddi A, Galetti C, Illuminati B, et al. Meta-analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease. J Int Med Res. 1996; 24(5): 389–406.
  46. Brevetti G, Giugliano G, Brevetti L, et al. Inflammation in peripheral artery disease. Circulation. 2010; 122(18): 1862–1875.
  47. Gibbons GW, Shaw PM, Gibbons GW, et al. Diabetic vascular disease: characteristics of vascular disease unique to the diabetic patient. Semin Vasc Surg. 2012; 25(2): 89–92.
  48. Ciszewicz M, Polubinska A, Antoniewicz A, et al. Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. Transl Res. 2009; 153(3): 118–123.
  49. Kristová V, Lísková S, Sotníková R, et al. Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats. Physiol Res. 2008; 57(3): 491–494.
  50. Koblik T, Sieradzki J, Sendur R, et al. The effect of insulin and sulodexide (Vessel Due F) on diabetic foot syndrome: pilot study in elderly patients. J Diabetes Complications. 2001; 15(2): 69–74.
  51. Andreozzi GM. Sulodexide in the treatment of chronic venous disease. Am J Cardiovasc Drugs. 2012; 12(2): 73–81.
  52. Krasiński Z, Biskupski P, Dzieciuchowicz Ł, et al. The influence of elastic components of the venous wall on the biomechanical properties of different veins used for arterial reconstruction. Eur J Vasc Endovasc Surg. 2010; 40(2): 224–229.
  53. Clarke GH, Vasdekis SN, Hobbs JT, et al. Venous wall function in the pathogenesis of varicose veins. Surgery. 1992; 111(4): 402–408.
  54. Travers JP, Brookes CE, Evans J, et al. Assessment of wall structure and composition of varicose veins with reference to collagen, elastin and smooth muscle content. Eur J Vasc Endovasc Surg. 1996; 11(2): 230–237.
  55. Ono T, Bergan JJ, Schmid-Schönbein GW, et al. Monocyte infiltration into venous valves. J Vasc Surg. 1998; 27(1): 158–166.
  56. Saviano M, Maleti O, Liguori L. Double-blind, double-dummy, randomized, multi-centre clinical assessment of the efficacy, tolerability and dose-effect relationship of sulodexide in chronic venous insufficiency. Curr Med Res Opin. 1993; 13(2): 96–108.
  57. Elleuch N, Zidi H, Bellamine Z, et al. CVD study investigators. Sulodexide in patients with chronic venous disease of the lower limbs: clinical efficacy and impact on quality of life. Adv Ther. 2016; 33(9): 1536–1549.
  58. Andreozzi GM. Sulodexide in the treatment of chronic venous disease. Am J Cardiovasc Drugs. 2012; 12(2): 73–81.
  59. Krasiński Z, Krasińska B, Pawlaczyk K, et al. The role of pharmacotherapy in the treatment of venous leg ulcers. Acta Angiol. 2010; 16(4): 145–157.
  60. Ligi D, Mosti G, Croce L, et al. Chronic venous disease — part II: Proteolytic biomarkers in wound healing. Biochim Biophys Acta. 2016; 1862(10): 1900–1908.
  61. Scondotto G, Aloisi D, Ferrari P, et al. Treatment of venous leg ulcers with sulodexide. Angiology. 2016; 50(11): 883–889.
  62. Coccheri S, Scondotto G, Agnelli G, et al. Venous arm of the SUAVIS (Sulodexide Arterial Venous Italian Study) Group. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost. 2002; 87(6): 947–952.
  63. Kucharzewski M, Franek A, Koziolek H. Treatment of venous leg ulcers with sulodexide. Phlebologie. 2017; 32(05): 115–120.
  64. Zou Y-X, Feng X, Jing ZP. Efficacy and safety of sulodexide in the treatment of venous ulcers of leg. Pharm Care Res. 2007; 7(1): 22–24.
  65. Nelson EA, Adderley U. Venous leg ulcers. BMJ Clin Evid. 2016; 2016: 1902.
  66. Gloviczki P, Comerota AJ, Dalsing MC, et al. Society for Vascular Surgery, American Venous Forum. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011; 53(Suppl 5): 2S–48S.
  67. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(Suppl 6): 454S–545S.
  68. Jawień A, Szewczyk M, Kaszuba A, et al. Grupa Ekspertów. Wytyczne Grupy Ekspertów w sprawie gojenia owrzodzeń żylnych goleni. Leczenie Ran. 2011; 8(3): 59–80.
  69. Mosti G, De Maeseneer M, Cavezzi A, et al. Society for Vascular Surgery and American Venous Forum Guidelines on the management of venous leg ulcers: the point of view of the International Union of Phlebology. Int Angiol. 2015; 34(3): 202–218.
  70. Wittens C, Davies AH, Bækgaard N, et al. Editor's choice — management of chronic venous disease. Eur J Vasc Endovasc Surg. 2015; 49(6): 678–737.
  71. Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Part I. Int Angiol. 2018; 37(3): 181–254.
  72. Nicolaides AN, Allegra C, Bergan J, et al. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Int Angiol. 2008; 27(1): 1–59.
  73. Luzzi R, Belcaro G, Dugall M, et al. The efficacy of sulodexide in the prevention of postthrombotic syndrome. Clin Appl Thromb Hemost. 2014; 20(6): 594–596.
  74. Bergan JJ, Schmid-Schönbein GW, Smith PD, et al. Chronic venous disease. N Engl J Med. 2006; 355(5): 488–498.
  75. Nicolaides AN. Chronic venous disease and the leukocyte-endothelium interaction: from symptoms to ulceration. Angiology. 2005; 56(Suppl 1): 11–19.
  76. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007; 92(2): 199–205.
  77. Errichi BM, Cesarone MR, Belcaro G, et al. Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry. Angiology. 2004; 55(3): 243–249.
  78. Tomkowski W, Kuca P, Urbanek T. Żylna choroba zakrzepowo-zatorowa — wytyczne profilaktyki, diagnostyki i terapii. Konsensus Polski 2017. Acta Angiol. 2017; 23(2): 73–113.
  79. Tomkowski W, Dybowska M, Dybowski D, et al. Przedłużona profilaktyka nawrotu żylnej choroby zakrzepowo-zatorowej. Medycyna po Dyplomie. 2018; 3: 3.
  80. Kesieme E, Kesieme C, Jebbin N, et al. Deep vein thrombosis: a clinical review. J Blood Med. 2011; 2011(2): 59–69.
  81. Chmielewski D, Górecki A, Kusz D, et al. Zasady profilaktyki żylnej choroby zakrzepowo-zatorowej w ortopedii i traumatologii narządu ruchu (aktualizacja z dnia 18 lutego 2014). Ortop Traumatol Rehabil. 2014; 16(2): 227–239.
  82. Ramelet AA, Monti M. Flebologia — przewodnik. Via Medica, Warszawa 2003.

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k. ul. Świętokrzyska 73, 80–180 Gdańsk

tel.: +48 58 320 94 94, faks:+48 58 320 94 60,  e-mail: viamedica@viamedica.pl